Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 11/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | CASP1 | P29466 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | IL1B | P01584 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249655 | 0.95 | XIAP (0.41) | XIAPMMP2ANPEPCYP3A4SMN1; SMN2 | |
| SCHEMBL10201818 | 0.91 | XIAP (0.38) | XIAPCYP3A4CASP1SMN1; SMN2 | |
| SCHEMBL10201832 | 0.90 | MAOB (0.40) | XIAPSMN1; SMN2 | |
| SCHEMBL10199324 | 0.86 | XIAP (0.46) | XIAPCYP3A4CASP1IL1B | |
| SCHEMBL644704 | 0.86 | CASP1 (0.47) | XIAPCYP3A4CASP1 | |
| SCHEMBL644702 | 0.86 | CASP1 (0.47) | XIAPCYP3A4CASP1 | |
| SCHEMBL10248511 | 0.85 | XIAP (0.38) | XIAPCYP3A4SMN1; SMN2 | |
| SCHEMBL10200499 | 0.85 | XIAP (0.38) | XIAPCYP3A4SMN1; SMN2 | |
| SCHEMBL10201206 | 0.85 | XIAP (0.42) | XIAPCYP3A4CASP1 | |
| SCHEMBL10200507 | 0.84 | MAPT (0.40) | XIAPSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | BATCHELOR MARK J | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | XIAP 257/4885MMP2 317/4885ANPEP 82/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | XIAP 257/4885MMP2 317/4885ANPEP 82/4885 |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | XIAP 276/4885MMP2 212/4885ANPEP 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.